Meg Wood

Direttore/Membro del Consiglio presso

Aronora, Inc.

Health Technology

Finance

Consumer Services

Profilo

Meg Wood is a venture capital business development executive with experience creating emerging growth strategies for portfolio investment.
As the Managing Director of NYBC Ventures, Meg oversees deal execution and management.
Board Observer for NYBC Ventures portfolio companies Catena Biosciences and KaloCyte.
Previously, Meg built and managed a $50 million fund for scientific research and innovation for a rare disease as the Vice President of Business Development at CD Ventures.
She has deep experience deploying investment capital for mission-oriented fund structures.
Prior to her role at CD Ventures, she held positions at MPM Capital, Tufts Medical Center and Boston Medical Center.
She received Master’s degrees in social work and public health from Boston University and her BA from the College of Charleston.

Posizioni attive di Meg Wood

Società	Posizione	Inizio
Nybc Ventures Nybc Ventures Investment ManagersFinance NYBC Ventures invests in companies located in the United States. The firm targets companies operating in the fields of blood & cellular therapies and related technologies. It provides financing for early stage capital requirements.	Investitore di Private Equity	01/04/2022
New York Blood Center, Inc. New York Blood Center, Inc. Medical/Nursing ServicesHealth Services Operates as blood collection and distribution organization	Investitore di Private Equity	01/09/2021
Aronora, Inc. Aronora, Inc. Pharmaceuticals: MajorHealth Technology Engages in development of biologic drugs	Direttore/Membro del Consiglio	01/07/2023
Rarebase, PBC Rarebase, PBC BiotechnologyHealth Technology Provides drug discovery services	Consulente / Consigliere	01/08/2021
Thymmune Therapeutics Thymmune Therapeutics BiotechnologyHealth Technology Operates as a preclinical stage biotechnology company that develops regenerative thymic cell therapies for the treatment of posttransplant organ tolerance, immunodeficiencies and autoimmune diseases	Direttore/Membro del Consiglio	01/03/2023
KaloCyte, Inc. KaloCyte, Inc. BiotechnologyHealth Technology Develops red blood cell substitutes used for trauma care related treatments	Direttore/Membro del Consiglio	01/05/2022

Tutte le posizioni attive di Meg Wood

Precedenti posizioni note di Meg Wood

Società	Posizione	Fine
CureDuchenne Ventures LLC CureDuchenne Ventures LLC Investment ManagersFinance CureDuchenne Ventures seeks investment opportunities located in the United States. The firm targets companies operating in the fields of health technology companies. It provides financing for early-stage capital requirements.	Investitore di Private Equity	01/08/2021
MPM BioImpact LLC MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions.	Investitore di Private Equity	01/06/2016
Catena Biosciences, Inc. Catena Biosciences, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops therapeutics through protein conjugation technologies	Direttore/Membro del Consiglio	-

Vedi nel dettaglio l'esperienza di Meg Wood

Formazione di Meg Wood

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Vedi nel dettaglio l'esperienza di Meg Wood

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	11
New York Blood Center, Inc. New York Blood Center, Inc. Medical/Nursing ServicesHealth Services Operates as blood collection and distribution organization	Health Services
MPM BioImpact LLC MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions.	Finance
Boston University Boston University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
College of Charleston College of Charleston Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
CureDuchenne Ventures LLC CureDuchenne Ventures LLC Investment ManagersFinance CureDuchenne Ventures seeks investment opportunities located in the United States. The firm targets companies operating in the fields of health technology companies. It provides financing for early-stage capital requirements.	Finance
KaloCyte, Inc. KaloCyte, Inc. BiotechnologyHealth Technology Develops red blood cell substitutes used for trauma care related treatments	Health Technology
Aronora, Inc. Aronora, Inc. Pharmaceuticals: MajorHealth Technology Engages in development of biologic drugs	Health Technology
Rarebase, PBC Rarebase, PBC BiotechnologyHealth Technology Provides drug discovery services	Health Technology
Catena Biosciences, Inc. Catena Biosciences, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops therapeutics through protein conjugation technologies	Health Technology
Thymmune Therapeutics Thymmune Therapeutics BiotechnologyHealth Technology Operates as a preclinical stage biotechnology company that develops regenerative thymic cell therapies for the treatment of posttransplant organ tolerance, immunodeficiencies and autoimmune diseases	Health Technology
Nybc Ventures Nybc Ventures Investment ManagersFinance NYBC Ventures invests in companies located in the United States. The firm targets companies operating in the fields of blood & cellular therapies and related technologies. It provides financing for early stage capital requirements.	Finance